Association between N-terminal pro-brain natriuretic peptide levels and contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome

Clinical Cardiology

Volumn 37, Issue 8, 2014, Pages 485-492

  Kurtul, Alparslan ^a   Duran, Mustafa ^a   Yarlioglues, Mikail ^a   Murat, Sani Namik ^a   Demircelik, Muhammed Bora ^b   Ergun, Gokhan ^a   Acikgoz, Sadik Kadri ^a   Sensoy, Baris ^a   Cetin, Mustafa ^a   Ornek, Ender ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b TURGUT OZAL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; IOHEXOL; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CONTRAST MEDIUM; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS; ADVERSE EFFECTS; AGED; BLOOD; CHEMICALLY INDUCED; KIDNEY DISEASES; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UPREGULATION;

ACUTE CORONARY SYNDROME; AGED; BIOMARKERS; CONTRAST MEDIA; CREATININE; FEMALE; HUMANS; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PATIENT ADMISSION; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84906314821     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22291     Document Type: Article

References (53)

1. Goldfarb S, McCullough PA, McDermott J, et al. Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. Mayo Clin Proc. 2009; 84: 170-179.
2. Finn WF,. The clinical and renal consequences of contrast-induced nephropathy. Nephrol Dial Transplant. 2006; 21: i2-i10.
3. McCullough PA,. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008; 51: 1419-1428.
4. Recio-Mayoral A, Chaparro M, Prado B, et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol. 2007; 49: 1283-1288.
5. Lazaros G, Tsiachris D, Tousoulis D, et al. In-hospital worsening renal function is an independent predictor of one-year mortality in patients with acute myocardial infarction. Int J Cardiol. 2012; 155: 97-101.
6. Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004; 93: 1515-1519.
7. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004; 44: 1393-1399.
8. Senoo T, Motohiro M, Kamihata H, et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol. 2010; 105: 624-628.
9. McCullough PA, Stacul F, Becker CR, et al. CIN Consensus Working Panel. Contrast-Induced Nephropathy (CIN) Consensus Working Panel: executive summary. Rev Cardiovasc Med. 2006; 7: 177-197.
10. de Lemos JA, McGuire DK, Drazner MH,. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003; 362: 316-322.
11. Weber M, Dill T, Arnold R, et al. N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. Am Heart J. 2004; 148: 612-620.
12. Staub D, Jonas N, Zellweger MJ, et al. Use of N-terminal pro-B-type natriuretic peptide to detect myocardial ischemia. Am J Med. 2005; 118: 1287.
13. Omland T, de Lemos JA, Morrow DA, et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol. 2002; 89: 463-465.
14. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002; 106: 2913-2918.
15. Eren NK, Ertas F, Yuksek U, et al. Additive prognostic value of NT-proBNP over TIMI risk score in intermediate-risk patients with acute coronary syndrome. Turk Kardiyol Dern Ars. 2009; 37: 1-8.
16. Heeschen C, Hamm CW, Mitrovic V, et al. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004; 110: 3206-3212.
17. Tumlin J, Stacul F, Adam A, et al. CIN Consensus Working Panel. Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006; 98: 14K-20K.
18. Staub D, Zeller T, Trenk D, et al. Use of B-type natriuretic peptide to predict blood pressure improvement after percutaneous revascularisation for renal artery stenosis. Eur J Vasc Endovasc Surg. 2010; 40: 599-607.
19. Thomsen HS,. Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am J Roentgenol. 2003; 181: 1463-1471.
20. Laskey WK, Jenkins C, Selzer F, et al. NHLBI Dynamic Registry Investigators. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol. 2007; 50: 584-590.
21. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130: 461-470.
22. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms [review]. J Am Soc Echocardiogr. 1989; 2: 358-367.
23. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009; 54: 2205-2241.
24. McCullough PA, Soman SS,. Contrast-induced nephropathy. Crit Care Clin. 2005; 21: 261-280.
25. Fox CS, Muntner P, Chen AY, et al. Short-term outcomes of acute myocardial infarction in patients with acute kidney injury: a report from the national cardiovascular data registry. Circulation. 2012; 125: 497-504.
26. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997; 103: 368-375.
27. Wi J, Ko YG, Shin DH, et al. Prediction of contrast-induced nephropathy with persistent renal dysfunction and adverse long-term outcomes in patients with acute myocardial infarction using the Mehran risk score. Clin Cardiol. 2013; 36: 46-53.
28. Kragelund C, Gronning B, Kober L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005; 352: 666-675.
29. Anker SD, Von Haehling S,. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004; 90: 464-470.
30. Lanese DM, Yuan BH, Falk SA, Conger JD,. Effects of atriopeptin III on isolated rat afferent and efferent arterioles. Am J Physiol. 1991; 261 (6 pt 2): F1102-F1109.
31. Jarai R, Dangas G, Huber K, et al. B-type natriuretic peptide and risk of contrast-induced acute kidney injury in acute ST-segment-elevation myocardial infarction: a substudy from the HORIZONS-AMI trial. Circ Cardiovasc Interv. 2012; 5: 813-820.
32. Meyer T, Schwaab B, Gorge G, et al. Can serum NT-proBNP detect changes of functional capacity in patients with chronic heart failure? Z Kardiol. 2004; 93: 540-545.
33. Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008; 10: 824-839.
34. Sabatine MS, Morrow DA, de Lemos JA, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol. 2004; 44: 1988-1995.
35. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail. 2001; 7: 21-29.
36. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994; 74: 1141-1148.
37. Ruiz-Ortega M, Lorenzo O, Egido J,. Angiotensin III increases MCP-1 and activates NF-kappaB and AP-1 in cultured mesangial and mononuclear cells. Kidney Int. 2000; 57: 2285-2298.
38. Jarai R, Huber K, Bogaerts K, et al. ASSENT IV-PCI investigators. Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial. Am Heart J. 2010; 159: 131-140.
39. Goldenberg I, Matetzky S,. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005; 172: 1461-1471.
40. Ronco C, McCullough P, Anker SD, et al. Acute Dialysis Quality Initiative (ADQI) consensus group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010; 31: 703-711.
41. Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008; 52: 1527-1539.
42. Heyman SN, Reichman J, Brezis M,. Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. Invest Radiol. 1999; 34: 685-691.
43. McCullough PA,. Acute kidney injury with iodinated contrast. Crit Care Med. 2008; 36 (4 suppl): S204-2S11.
44. Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 2002; 91: 1127-1134.
45. Kawakami R, Saito Y, Kishimoto I, et al. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation. 2004; 110: 3306-3312.
46. Vila G, Resl M, Stelzeneder D, et al. Plasma NT-proBNP increases in response to LPS administration in healthy men. J Appl Physiol (1985). 2008; 105: 1741-1745.
47. Madak N, Nazli Y, Mergen H, et al. Acute phase reactants in patients with coronary slow flow phenomenon. Anadolu Kardiyol Derg. 2010; 10: 416-420.
48. Hopkins WE, Chen Z, Fukagawa NK, et al. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation. 2004; 109: 2872-2877.
49. Hizoh I, Strater J, Schick CS, et al. Radiocontrast-induced DNA fragmentation of renal tubular cells in vitro: role of hypertonicity. Nephrol Dial Transplant. 1998; 13: 911-918.
50. Qin S, Ding J, Takano T, et al. Involvement of receptor aggregation and reactive oxygen species in osmotic stress-induced Syk activation in B cells. Biochem Biophys Res Commun. 1999; 262: 231-236.
51. Bittner A, Alcaino H, Castro PF, et al. Matrix metalloproteinase-9 activity is associated to oxidative stress in patients with acute coronary syndrome. Int J Cardiol. 2010; 143: 98-100.
52. McCullough PA, Adam A, Becker CR, et al. CIN Consensus Working Panel. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006; 98: 27K-36K.
53. Cho JY, Jeong MH, Hwan Park S, et al. Effect of contrast-induced nephropathy on cardiac outcomes after use of nonionic isosmolar contrast media during coronary procedure. J Cardiol. 2010; 56: 300-306.